vimarsana.com

Latest Breaking News On - Efficacy results - Page 14 : vimarsana.com

Outlook Therapeutics to Present at the 14th Asia-Pacific

Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial.

United statesUnited kingdomSuber huangJenene thomasAsia pacific vitreoSubers huangHarriet ullmanLavoie health scienceAsia pacific academy of ophthalmologyOutlook therapeutics incCongress onRetina centerRetina societyOutlook therapeutic phaseAsia pacific vitreo retina societyOutlook therapeutics

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),.

United statesHong kongAscentage pharmaYifan zhaiAmerican society of hematologyMajor nationalEuropean unionMd anderson cancer centerDana farber cancer instituteAmerican societyEfficacy resultsNovel third generationKinase inhibitorResistant chronic myeloid leukemiaPivotal phaseTyrosine kinase inhibitor

Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

/PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address.

United statesSan antonioTomasz rzymskiPawel przewiezlikowskiSujan piyaMd washington universityMd anderson cancer centerWarsaw stock exchangeSaint louis washington university school of medicinePhd md anderson cancer centerHenryb gonzalez convention centreMenarini groupAlessandro paoli menarini groupAmerican society of hematology annual meeting expositionProgram numberAmerican society

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting

Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA

United statesKristin bhavnaniStephana gruppGregory yanikMeagana jacobyVyxeos liposomalDaniel riveraMohamad mohtyGuillermo montalban bravoPierre peterlinVinod pullarkatAndrean flynnAnnalisa ruggeriKunhwa kimLiposomal cytarabineLuke maese

Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

/PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address.

United statesSan antonioTomasz rzymskiPawel przewiezlikowskiSujan piyaMd washington universityMd anderson cancer centerWarsaw stock exchangeSaint louis washington university school of medicinePhd md anderson cancer centerHenryb gonzalez convention centreMenarini groupAlessandro paoli menarini groupAmerican society of hematology annual meeting expositionProgram numberAmerican society

vimarsana © 2020. All Rights Reserved.